Eve is an expert in the economic evaluation of public health interventions in low- and middle-income countries. She has led multiple evaluations in malaria, TB, neglected tropical diseases and more recently non-communicable diseases. She takes a health-systems, equity focussed approach to all her work. Eves other interests are in policy analysis and knowledge translation, where she seeks to understand how scientific evidence can best inform health policy and improve outcomes.
Eve chairs the LSTM institutional Athena Swan self-assessment committee and serves on LSTM’s Equity and Inclusion Committee. In these roles and through her research, Eve strives to achieve equitable partnerships and to support people to achieve their career goals, with a particular focus on those who are underrepresented in public health.
Eve is an economist (BA Hons. Economics, University of Liverpool, 1997) with a PhD on the economics of climate-based malaria early warning systems (LSTM, 2001). She has worked as research fellow in the London School of Hygiene, a senior analyst at New Philanthropy Capital and with the global health consultancy firm, LATH. During her time at LATH Eve worked as a senior technical advisor, consultant team-leader and manager. She then moved into research programme management where she specialised in ensuring robust and equitable governance structures for complex consortia, before returning to full-time academia in 2020.
Selected research grants
She leads/led work packages on the following multidisciplinary, multi-partner research consortia:
- Multimorbidity-associated emergency hospital admissions: a “screen and link” strategy to improve outcomes for high-risk patients in sub-Saharan Africa. NIHR, £4.9m. 01/06/2021 - 31/05/2025
- PIIVeC: Partnership for Increasing the impact of Vector control. GCRF via MRC, £6.3m 01/10/2017 - 31/12/2021
- MIRA: Malaria in an insecticide resistant Africa. Wellcome Trust, £2.4M 01/03/2016 - 31/10/2019
She is also the senior health economist on the following major research projects
- STREAM2 phase-III multi-country non-inferiority randomised controlled trial to evaluate a shortened regimen for multi-drug resistant tuberculosis (MDR-TB). Vital Strategies & Janssen Research and Development, £744k. 30/03/2021 - 28/02/2023
- INTEGRATION Increasing the uptake of IPTp-SP through Seasonal Malaria Chemoprevention channel delivery. EDCTP, £3.4m. 01/04/2021 - 31/03/2024
- STOPMiP-2: Intermittent preventive treatment with dihydroartemisinin-piperaquine: a new malaria strategy to prevent adverse birth outcomes in Papua, Indonesia. MRC, £970k. 01/12/2020 - 31/07/2023
- Spatial intelligence system (SIS) for precision larviciding for malaria control. IVCC/BMGF £643k 01/01/2018 - 30/04/2021
- Eaves Tubes for malaria control: from concept to implementation. BMGF. £7.9m 01/01/2016 - 31/10/2021